ACST Stock – (NASDAQ: ACST) is actually providing an update on the use

ACST Stock – (NASDAQ: ACST) is actually providing an update on the use

ACST
-1.84%
As necessary pursuant to the policies of the TSX Venture Exchange, Acasti Pharma Inc. (“Acasti or maybe the “Company”) ACST Stock (NASDAQ: ACST – TSX-V: ACST) is actually giving an update on the use of its “at-the market” equity offering program.

As earlier disclosed, Acasti entered into an amended and restated ATM sales agreement on June twenty nine, 2020 (the “Sales Agreement”) with B. Riley FBR Inc., Oppenheimer & Co. Inc. along with H.C. Wainwright & Co., LLC (collectively, the “Agents”), to implement an “at-the market” equity offering program under which Acasti might issue and market from time to time the everyday shares of its having an aggregate offering price of up to seventy five dolars million in the Agents (the “ATM Program”).

ACST Stock – Pursuant to the ATM Program, as required pursuant to the policies of the TSX Venture Exchange (“TSXV”), since the last distributions reported on January 27, 2021, Acasti given an aggregate of 20,159,229 typical shares (the “ATM Shares”) with the NASDAQ Stock Market for aggregate yucky proceeds to the Company of US$21.7 huge number of. The ATM Shares had been marketed at prevailing market rates averaging US$1.0747 per share. No securities were sold throughout the facilities of the TSXV or, to the understanding of the Company, in Canada. The ATM Shares were sold pursuant to a U.S. registration statement on Form S-3 (No. 333 239538) as made effective on July seven, 2020, as well as the Sales Agreement. Pursuant to the Sales Agreement, a cash commission of 3.0 % on the aggregate yucky proceeds raised was paid to the Agents in connection with the services of theirs. As a direct result of the recent ATM sales, Acasti has a total of 200,119,659 common shares issued and superb as of March 5, 2021.

The additional capital raised has strengthened Acasti’s balance sheet and will provide the Company with additional flexibility in its ongoing review process to check out as well as evaluate strategic alternatives.

Approximately Acasti – ACST Stock

Acasti is a biopharmaceutical innovator that has historically centered on the research, commercialization and development of prescribed drugs making use of OM3 fatty acids delivered both as totally free fatty acids as well as bound-to-phospholipid esters, created from krill oil. OM3 fatty acids have substantial clinical evidence of efficacy and safety in lowering triglycerides in patients with HTG. CaPre, or hypertriglyceridemia, an OM3 phospholipid therapeutic, was being developed for individuals with severe HTG.

Forward Looking Statements – ACST Stock

Statements in this press release which aren’t statements of current or historical truth constitute “forward-looking information” within the meaning of Canadian securities laws as well as “forward-looking statements” to the meaning of U.S. federal securities laws (collectively, “forward looking statements”). Such forward looking claims involve known and unknown risks, uncertainties, as well as other unknown variables that may result in the particular results of Acasti to be materially different from historical results or from any future results expressed or implied by such forward looking statements. In addition to statements which explicitly describe such risks as well as uncertainties, readers are urged to consider statements marked with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “potential,” “should,” “may,” “will,” “plans,” “continue”, “targeted” or any other similar expressions to be uncertain and forward-looking. Readers are actually cautioned not to place undue reliance on these forward-looking statements, which speak only as of the particular date of this particular press release. Forward-looking statements in that press release include, but are not limited to, information or statements about Acasti’s strategy, succeeding operations as well as its review of strategic alternatives.

The forward looking claims contained in this press release are expressly qualified in their entirety by this alerting declaration, the “Special Note Regarding Forward-Looking Statements” section found in Acasti’s latest annual report on Form 10 K and quarterly report on Form 10-Q, which are actually readily available on EDGAR at www.sec.gov/edgar.shtml, on SEDAR at www.sedar.com and also on the investor section of Acasti’s site at www.acastipharma.com. All forward looking assertions in this press release are made as of the day of this particular press release.

ACST Stock – Acasti does not undertake to upgrade any such forward-looking statements whether as a direct result of information which is brand new, future events or perhaps otherwise, except as required by law. The forward-looking statements contained herein are also subject typically to assumptions and risks and uncertainties that are discussed from time to time in Acasti’s public securities filings with the Securities and exchange Commission and The Canadian securities commissions, like Acasti’s newest annual report on Form 10-K and quarterly report on Form 10-Q under the caption “Risk Factors“.

 

ACST Stock – (NASDAQ: ACST) is actually giving an update on the use